Impact News +++ Petros Pharma, Qualigen see dramatic rises amid social media buzz, short squeezes (SeekingAlpha) +++ QUALIGEN Aktie -3,45%

OUTLOOK THERAPEUTICS Aktie

>Aktienkurs

1.25 EUR +4.3% (Tradegate)

Ask: 1.26 EUR / 6400 Stück

Bid: 1.23 EUR / 6600 Stück

Tagesumsatz: 8694 Stück

Realtime Kurs von 8 bis 22 Uhr!

Intraday

1 Jahr

>Performance

1 Woche: -22,3%

1 Monat: -41,2%

3 Monate: -47,1%

6 Monate: -47,9%

1 Jahr: +7,7%

laufendes Jahr: +2,4%

>OUTLOOK THERAPEUTICS Aktie

Name:

OUTLOOK THERAPEUT. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US69012T2069 / A2PF3C

Symbol/ Ticker:

41ON (Frankfurt) / OTLK (NASDAQ)

Kürzel:

FRA:41ON, ETR:41ON, 41ON:GR, NASDAQ:OTLK

Index:

Webseite:

https://outlooktherapeuti..

Marktkapitalisierung:

243.33 Mio. EUR

Umsatz:

EBITDA:

-42.42 Mio. EUR

Gewinn je Aktie:

-0.276 EUR

Schulden:

10.32 Mio. EUR

Liquide Mittel:

17.4 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

10.55 / 19.26 / -

Gewinnm./ Eigenkapitalr.:

- / -418.99%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

OUTLOOK THERAPEUTICS, OUTLOOK THERAPEUTIC

Letzte Datenerhebung:

28.11.21

>Eigentümer

Aktien: 178.1 Mio. St.

f.h. Aktien: 107.02 Mio. St.

Insider Eigner: 38.5%

Instit. Eigner: 10.92%

Leerverk. Aktien: 6.1%

>Peer Group

ADICET

ANAPTYSBIO

APPLIED DNA

ASSURE HLDGS

BIO-RAD B

IGM BIOSCIENCES

INFINITY PHARMACEUTICALS

IVERIC BIO

SCHOLAR ROCK

VENUS CONCEPT

>Chart & Kurs - NASDAQ

>Alle News

24.11.21 - 17:08	Thinking about buying stock in Naked Brand, Biolase, Gap, Inspira Technologies, or Outlook Therapeutics? (PR Newswire)
	NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, BIOL, GPS, IINN, and OTLK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch A...

24.11.21 - 15:09	Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount (Benzinga)
	Outlook Therapeutics Inc (NASDAQ: OTLK) has increased the size of the previously announced read more...

24.11.21 - 14:57	Outlook Shares Plunges After Raising $500M Via Equity Offering Issued At 20% Discount (Benzinga)
	Outlook Therapeutics Inc (NASDAQ: OTLK) has increased the size of the previously announced read more...

24.11.21 - 06:54	Outlook Therapeutics secures $50M capital through stock offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.11.21 - 04:33	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million (GlobeNewswire EN)
	ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulati...

24.11.21 - 01:02	Outlook Therapeutics Down 17% After Hours on Stock Sale (MarketWatch)
	Outlook Therapeutics Down 17% After Hours on Stock Sale...

23.11.21 - 22:42	Outlook Therapeutics under pressure on plans to raise $10M in stock offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.11.21 - 22:33	Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire EN)
	ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevaci...

15.11.21 - 15:06	Outlook Therapeutics to file marketing application for for wet AMD therapy in Q1 2022 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.21 - 17:03	Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference (GlobeNewswire EN)
	- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data...

10.11.21 - 14:09	Outlook Therapeutics to Present at the Virtual Investor Roundtable Event (GlobeNewswire EN)
	Live moderated video webcast discussion among members of management and Thought Leaders Firas M. Rahhal, MD and Robert L. Avery, MD on Tuesday, November 16th at 9:00 AM ET Live moderated video webcast discussion among members of management and Though...

04.11.21 - 13:09	Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference (GlobeNewswire EN)
	Firas M. Rahhal, MD, will present Phase 3 pivotal data from the NORSE TWO registration trial on Saturday, November 13, 2021 Firas M. Rahhal, MD, will present Phase 3 pivotal data from the NORSE TWO registration trial on Saturday, November 13, 2021...

03.11.21 - 13:12	Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases (GlobeNewswire EN)
	Outlook Therapeutics management to present on Thursday, November 11, 2021 Outlook Therapeutics management to present on Thursday, November 11, 2021...

12.10.21 - 18:03	Outlook Therapeutics′ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab (GlobeNewswire EN)
	Strong safety data from NORSE THREE registration trial consistent with other trials for ONS-5010 and in prior published research Strong safety data from NORSE THREE registration trial consistent with other trials for ONS-5010 and in prior published...

07.10.21 - 14:09	Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting (GlobeNewswire EN)
	Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics' NORSE THREE registration trial on Tuesday, October 12, 2021 Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics' NORSE THREE registration t...

05.10.21 - 14:09	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire EN)
	Outlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Thursday, October 7, 2021 Outlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Th...

01.10.21 - 21:48	Outlook Therapeutics (OTLK) Investor Presentation - Slideshow (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.09.21 - 14:33	Outlook Therapeutics reports 12-month safety data from late-stage bevacizumab-vikg study in wet AMD (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.09.21 - 14:09	Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial (GlobeNewswire EN)
	ISELIN, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications,...

21.09.21 - 14:06	Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference (GlobeNewswire EN)
	Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Zitat des Tages: Die Welt verliert im Toten nur einen Menschen; aber der Mensch verliert die Welt. - Christian Friedrich Hebbel

Partner: >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf Twitter |

Börsentreff auf Instagram